Joint Filing Agreement
Exhibit 99.7
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.001 per share, of Pandion Therapeutics, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement as of the date set forth below.
| Date: March 4, 2021 | MERCK & CO. INC. | |||||
| /s/ Xxxxxx X. Xxxxx | ||||||
| Name: | Xxxxxx X. Xxxxx | |||||
| Title: | Executive Vice President, Global Services and Chief Financial Officer | |||||
| MERCK SHARP & DOHME CORP. | ||||||
| /s/ Xxxxx X. Xxxxx | ||||||
| Name: | Xxxxx X. Xxxxx | |||||
| Title: | Senior Vice President, Corporate Development | |||||
| PANAMA MERGER SUB, INC. | ||||||
| /s/ Xxxx Xxxxxxxx | ||||||
| Name: | Xxxx Xxxxxxxx | |||||
| Title: | President | |||||
